These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Effects of experimental recombinant interferons on multiple sclerosis. Johnson KP; Panitch HS Trans Am Clin Climatol Assoc; 1989; 100():171-6. PubMed ID: 2479162 [No Abstract] [Full Text] [Related]
10. Interferon: the quintessence of a quinquagenarian. De Clercq E Verh K Acad Geneeskd Belg; 2009; 71(1-2):5-14. PubMed ID: 19739395 [TBL] [Abstract][Full Text] [Related]
11. A role for the interferon system in the pathogenesis of multiple sclerosis? Billiau A; Carton H; Heirwegh K J Biol Regul Homeost Agents; 1987; 1(1):9-22. PubMed ID: 2461051 [TBL] [Abstract][Full Text] [Related]
12. [Actual status of multiple sclerosis in Cuba. National cooperative group for the clinical trial "Recombinant interferon alpha-2b in multiple sclerosis"]. Cabrera-Gómez JA; Santana-Capote E; Echazábal-Santana N; Díaz de la Fe A; Casanova M; Gómez L; Báez-Martín MM; González-Quevedo A; Fernández R; Vals O; Peña A; Rodríguez A; Cabrera-Núñez JA; Moscoso ME; Ruiz M Rev Neurol; 2000 Sep 1-15; 31(5):482-93. PubMed ID: 11027103 [TBL] [Abstract][Full Text] [Related]
13. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis]. Seres E; Vécsei L Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710 [TBL] [Abstract][Full Text] [Related]
14. [Current methods of the multiple sclerosis treatment]. Kovalenko PA; Shamanskiĭ SV; Baziĭ NI Voen Med Zh; 2001 Oct; 322(10):45-52. PubMed ID: 11764483 [No Abstract] [Full Text] [Related]
16. [Interferons in multiple sclerosis]. Tintoré M Rev Neurol; 1997 Feb; 25(138):267-9. PubMed ID: 9147755 [No Abstract] [Full Text] [Related]
17. The interferon system as a basis for antiviral therapy or prophylaxis. Billiau A Verh K Acad Geneeskd Belg; 1986; 48(3):187-220. PubMed ID: 2430375 [No Abstract] [Full Text] [Related]
18. Interferon. Clinical uses and nursing implications. Jordan K J Intraven Nurs; 1990; 13(6):388-91. PubMed ID: 1700813 [TBL] [Abstract][Full Text] [Related]
19. In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentary. Hutchinson M Mult Scler; 2013 Jan; 19(1):29-30. PubMed ID: 23303882 [No Abstract] [Full Text] [Related]
20. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Weinstock-Guttman B; Ransohoff RM; Kinkel RP; Rudick RA Ann Neurol; 1995 Jan; 37(1):7-15. PubMed ID: 7529476 [No Abstract] [Full Text] [Related] [Next] [New Search]